c-MET (T992I)

MET · Variant type: point · HGVS: p.T992I

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Cabozantinib	98.1%	1.9%	92.73
2	Tepotinib	96.5%	3.5%	99.75
3	Crizotinib	95.9%	4.1%	91.39
4	Capmatinib	93.6%	6.4%	99.75
5	Tivozanib	89.6%	10.4%	92.42
6	Deucravacitinib	88.8%	11.2%	98.99
7	Gilteritinib	88.6%	11.4%	88.97
8	Erdafitinib	73.6%	26.4%	95.71
9	Pacritinib	68.2%	31.8%	88.64
10	Selpercatinib	59.5%	40.5%	96.72
11	Afatinib	53.7%	46.3%	98.50
12	Defactinib	52.2%	47.8%	92.68
13	Lenvatinib	50.4%	49.6%	97.74
14	Repotrectinib	48.5%	51.5%	84.21
15	Dacomitinib	46.2%	53.8%	97.99
16	Fostamatinib	45.4%	54.6%	96.74
17	Canertinib	39.8%	60.2%	96.49
18	Dabrafenib	38.4%	61.6%	94.74
19	Imatinib	35.8%	64.2%	99.00
20	Vemurafenib	35.4%	64.6%	96.49
21	Pazopanib	33.2%	66.8%	97.49
22	Fedratinib	32.7%	67.3%	96.21
23	Neratinib	32.1%	67.9%	93.18
24	Trametinib	28.5%	71.5%	99.50
25	Abemaciclib	27.2%	72.8%	91.48

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Cabozantinib	98.1%	—	—
Tepotinib	96.5%	—	—
Crizotinib	95.9%	—	—
Capmatinib	93.6%	—	—
Tivozanib	89.6%	—	—
Deucravacitinib	88.8%	—	—
Gilteritinib	88.6%	—	—
Erdafitinib	73.6%	—	—
Pacritinib	68.2%	—	—
Selpercatinib	59.5%	—	—
Afatinib	53.7%	—	—
Defactinib	52.2%	—	—
Lenvatinib	50.4%	—	—
Repotrectinib	48.5%	—	—
Dacomitinib	46.2%	—	—
Fostamatinib	45.4%	—	—
Canertinib	39.8%	—	—
Dabrafenib	38.4%	—	—
Imatinib	35.8%	—	—
Vemurafenib	35.4%	—	—
Pazopanib	33.2%	—	—
Fedratinib	32.7%	—	—
Neratinib	32.1%	—	—
Trametinib	28.5%	—	—
Abemaciclib	27.2%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.8ms